NicoleLamannaMD

Hematologic Oncology

Assistant Professor, Medicine, Weill Cornell Medical College

Overview of Dr. Lamanna

Dr. Nicole Lamanna is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, NewYork-Presbyterian/Columbia University Irving Medical Center, and Memorial Sloan Kettering Cancer Center. She received her medical degree from Albert Einstein College of Medicine of Yeshiva University and has been in practice 20 years. Dr. Lamanna accepts several types of health insurance, listed below. She is one of 495 doctors at Memorial Sloan Kettering Cancer Center and one of 379 doctors at New York-Presbyterian Hospital who specialize in Oncology. She has more than 90 publications and over 500 citings.

Office
622 W 168th St
New York, NY 10032
Book by Phone+1(978) 208-2124

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2001 - 2004
NYU Grossman School of MedicineResidency, Internal Medicine, 1997 - 2000
Albert Einstein College of MedicineClass of 1997

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 1998 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

New York Magazine: Top Doctors Castle Connolly, 2014
Top Doctors: New York Metro Area Castle Connolly, 2014

Clinical Trials

Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma Start of enrollment: 1996 Mar 01
Completed
Phase 3
Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2005 May 01
Completed
Phase 2
Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer Start of enrollment: 2005 Jul 01
Completed
Phase 1, Phase 2
Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia Start of enrollment: 2009 Jul 01
Completed
Phase 1
Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age Start of enrollment: 2009 Nov 06
Completed
Phase 2
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2014 Feb 05
Terminated
Phase 3
Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia Start of enrollment: 2018 Nov 12
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

6 citations
Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study.
Mazyar Shadman, Beenish S Manzoor, Kavita Sail, Hande H Tuncer, John N Allan
Clinical Lymphoma, Myeloma & Leukemia. 2023-07-01
314 citations
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Anthony R. Mato, Chadhi Nabhan, Meghan C. Thompson, Nicole Lamanna, Danielle M. Brander
Haematologica. 2018-05-01
192 citations
A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia
Susan O'Brien, Nicole Lamanna, Thomas J. Kipps, Ian W. Flinn, Andrew D. Zelenetz
Blood. 2015-12-17

Journal Articles

Clonal Diversity Predicts Adverse Outcome in Chronic Lymphocytic Leukemia
Vincent Miller, Tariq Mughal, Nicole Lamanna, Andrew Zelenetz, Mark L Heaney, Mark G Frattini, Nature
Real World Outcomes and Management Strategies for Venetoclax-Treated Chronic Lymphocytic Leukemia Patients in the United States
Arun K Singavi, Andrew Zelenetz, Nicole Lamanna, Bruce D Cheson, Richard R Furman, Jakub Svoboda, Stephen J Schuster, John N Allan, Chaitra S Ujjani, Haematologica
The Phase 3 DUO Trial: Duvelisib Versus Ofatumumab in Relapsed and Refractory CLL/SLL
Matthew S Davids, Ian W Flinn, Craig A Portell, Nicole Lamanna, Scott Lunin, Amanda F Cashen, Blood

Abstracts/Posters

Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...
Nicole Lamanna, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
Nicole Lamanna, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
Nicole Lamanna, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
Nicole Lamanna, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Combination Thioguanine and Decitabine Is Highly Active in Patients with Advanced Myeloid Malignancies: A Single Institution Experience
Nicole Lamanna, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study
Nicole Lamanna, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...
Nicole Lamanna, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Evolution in Practice Patterns and Differences Among Experts and Community Healthcare Providers in the Treatment of Patients with Chronic Lymphocytic Leukemia
Nicole Lamanna, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients
Nicole Lamanna, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
Nicole Lamanna, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

“Great Therapies for All-Comers” in CLL: How Can Oncologists “Pick and Choose?”April 18th, 2023
Oncternal Therapeutics : Lee 2022 ASCO Poster Zilovertamab + Ibrutinib for MCL and CLLJune 7th, 2022
Clinical Challenges: Optimizing CLL TreatmentDecember 17th, 2021
Join now to see all

Professional Memberships

American College of Physicians - ACP
Member

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS California PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment